Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN™ Rapamycin in Microcystic LMs, Plans H2 2026 NDA

summarizeSummary

Palvella Therapeutics reported highly positive topline results from its Phase 3 SELVA study of QTORIN™ rapamycin for microcystic lymphatic malformations, meeting all primary and secondary endpoints and paving the way for an NDA submission in the second half of 2026.

check_boxKey Events

• Positive Phase 3 Results

  QTORIN™ rapamycin met its primary endpoint and all secondary efficacy endpoints in the SELVA study for microcystic lymphatic malformations (mLM-IGA mean improvement of +2.13; p<0.001).

• High Efficacy & Tolerability

  95% of participants aged ≥ 6 showed improvement, with 86% rated "Much Improved" or "Very Much Improved." The drug was well-tolerated with no drug-related serious adverse events.

• NDA Submission Planned

  Palvella plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, targeting potential U.S. approval in the first half of 2027.

• First-in-Class Potential

  If approved, QTORIN™ rapamycin would be the first FDA-approved therapy for microcystic LMs, a rare disease affecting over 30,000 individuals in the U.S.

auto_awesomeAnalysis

This 8-K announces a significant positive catalyst for Palvella Therapeutics. The successful Phase 3 trial for QTORIN™ rapamycin, demonstrating statistically significant improvement and good tolerability in microcystic lymphatic malformations, de-risks the lead product candidate considerably. With Breakthrough Therapy, Orphan Drug, and Fast Track designations, and plans for an NDA submission in H2 2026, the company is on track to potentially launch the first FDA-approved therapy for an estimated 30,000 patients. This outcome validates Palvella's QTORIN™ platform and could be a major value driver, transforming the company's commercial prospects. Investors should monitor the NDA submission and subsequent regulatory review process.